Logo image of CRSP

CRISPR THERAPEUTICS AG (CRSP) Stock Fundamental Analysis

NASDAQ:CRSP - Nasdaq - CH0334081137 - Common Stock - Currency: USD

44.25  -0.18 (-0.41%)

After market: 44.2999 +0.05 (+0.11%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CRSP. CRSP was compared to 557 industry peers in the Biotechnology industry. CRSP has a great financial health rating, but its profitability evaluates not so good. CRSP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRSP has reported negative net income.
CRSP had a negative operating cash flow in the past year.
In the past 5 years CRSP reported 4 times negative net income.
In the past 5 years CRSP reported 4 times negative operating cash flow.
CRSP Yearly Net Income VS EBIT VS OCF VS FCFCRSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M

1.2 Ratios

CRSP's Return On Assets of -17.80% is fine compared to the rest of the industry. CRSP outperforms 78.99% of its industry peers.
CRSP has a Return On Equity of -21.08%. This is amongst the best in the industry. CRSP outperforms 84.56% of its industry peers.
Industry RankSector Rank
ROA -17.8%
ROE -21.08%
ROIC N/A
ROA(3y)-17.4%
ROA(5y)-11.51%
ROE(3y)-20.59%
ROE(5y)-13.4%
ROIC(3y)N/A
ROIC(5y)N/A
CRSP Yearly ROA, ROE, ROICCRSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRSP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRSP Yearly Profit, Operating, Gross MarginsCRSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

8

2. Health

2.1 Basic Checks

CRSP does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRSP has more shares outstanding than it did 1 year ago.
CRSP has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CRSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRSP Yearly Shares OutstandingCRSP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRSP Yearly Total Debt VS Total AssetsCRSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

An Altman-Z score of 6.12 indicates that CRSP is not in any danger for bankruptcy at the moment.
CRSP has a Altman-Z score of 6.12. This is amongst the best in the industry. CRSP outperforms 80.43% of its industry peers.
There is no outstanding debt for CRSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.12
ROIC/WACCN/A
WACC4.97%
CRSP Yearly LT Debt VS Equity VS FCFCRSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 15.64 indicates that CRSP has no problem at all paying its short term obligations.
The Current ratio of CRSP (15.64) is better than 88.51% of its industry peers.
A Quick Ratio of 15.64 indicates that CRSP has no problem at all paying its short term obligations.
CRSP has a better Quick ratio (15.64) than 88.51% of its industry peers.
Industry RankSector Rank
Current Ratio 15.64
Quick Ratio 15.64
CRSP Yearly Current Assets VS Current LiabilitesCRSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

4

3. Growth

3.1 Past

CRSP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -66.18%.
The Revenue for CRSP has decreased by -86.13% in the past year. This is quite bad
CRSP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -33.62% yearly.
EPS 1Y (TTM)-66.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.49%
Revenue 1Y (TTM)-86.13%
Revenue growth 3Y-65.58%
Revenue growth 5Y-33.62%
Sales Q2Q%71.63%

3.2 Future

The Earnings Per Share is expected to grow by 29.01% on average over the next years. This is a very strong growth
Based on estimates for the next years, CRSP will show a very strong growth in Revenue. The Revenue will grow by 177.87% on average per year.
EPS Next Y-26.78%
EPS Next 2Y-1.96%
EPS Next 3Y4.77%
EPS Next 5Y29.01%
Revenue Next Year217.06%
Revenue Next 2Y249.82%
Revenue Next 3Y201.27%
Revenue Next 5Y177.87%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRSP Yearly Revenue VS EstimatesCRSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
CRSP Yearly EPS VS EstimatesCRSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRSP. In the last year negative earnings were reported.
Also next year CRSP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRSP Price Earnings VS Forward Price EarningsCRSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRSP Per share dataCRSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.96%
EPS Next 3Y4.77%

More info and screens

0

5. Dividend

5.1 Amount

CRSP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRISPR THERAPEUTICS AG

NASDAQ:CRSP (6/20/2025, 8:27:08 PM)

After market: 44.2999 +0.05 (+0.11%)

44.25

-0.18 (-0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners76.63%
Inst Owner Change-1.13%
Ins Owners1.69%
Ins Owner Change0.34%
Market Cap3.82B
Analysts76.47
Price Target81.69 (84.61%)
Short Float %24.21%
Short Ratio9.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)19.61%
Min EPS beat(2)-23.86%
Max EPS beat(2)63.08%
EPS beat(4)3
Avg EPS beat(4)18.42%
Min EPS beat(4)-23.86%
Max EPS beat(4)63.08%
EPS beat(8)6
Avg EPS beat(8)218.16%
EPS beat(12)9
Avg EPS beat(12)153.76%
EPS beat(16)11
Avg EPS beat(16)124.7%
Revenue beat(2)1
Avg Revenue beat(2)128.37%
Min Revenue beat(2)-86.95%
Max Revenue beat(2)343.7%
Revenue beat(4)1
Avg Revenue beat(4)19.94%
Min Revenue beat(4)-91.33%
Max Revenue beat(4)343.7%
Revenue beat(8)3
Avg Revenue beat(8)481.23%
Revenue beat(12)4
Avg Revenue beat(12)324.33%
Revenue beat(16)6
Avg Revenue beat(16)272.51%
PT rev (1m)-1.33%
PT rev (3m)-1.56%
EPS NQ rev (1m)-5.5%
EPS NQ rev (3m)-14.81%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.35%
Revenue NQ rev (1m)-15.99%
Revenue NQ rev (3m)-30.77%
Revenue NY rev (1m)2.4%
Revenue NY rev (3m)-13.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 101.43
P/FCF N/A
P/OCF N/A
P/B 2.09
P/tB 2.09
EV/EBITDA N/A
EPS(TTM)-4.52
EYN/A
EPS(NY)-4.54
Fwd EYN/A
FCF(TTM)-3.56
FCFYN/A
OCF(TTM)-3.55
OCFYN/A
SpS0.44
BVpS21.18
TBVpS21.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.8%
ROE -21.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.4%
ROA(5y)-11.51%
ROE(3y)-20.59%
ROE(5y)-13.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.23%
Cap/Sales 3.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.64
Quick Ratio 15.64
Altman-Z 6.12
F-Score2
WACC4.97%
ROIC/WACCN/A
Cap/Depr(3y)74.64%
Cap/Depr(5y)175.56%
Cap/Sales(3y)1036.11%
Cap/Sales(5y)1149.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-66.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.49%
EPS Next Y-26.78%
EPS Next 2Y-1.96%
EPS Next 3Y4.77%
EPS Next 5Y29.01%
Revenue 1Y (TTM)-86.13%
Revenue growth 3Y-65.58%
Revenue growth 5Y-33.62%
Sales Q2Q%71.63%
Revenue Next Year217.06%
Revenue Next 2Y249.82%
Revenue Next 3Y201.27%
Revenue Next 5Y177.87%
EBIT growth 1Y-58.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.16%
EBIT Next 3Y0.42%
EBIT Next 5Y20.04%
FCF growth 1Y18.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.86%
OCF growth 3YN/A
OCF growth 5YN/A